Effects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected persons
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
OBJECTIVE: To distinguish the effects of drug abuse, mental disorders, and problem drinking on antiretroviral therapy (ART) and highly active ART (HAART) use.
DESIGN: Prospective population-based probability sample of 2,267 (representing 213,308) HIV-infected persons in care in the United States in early 1996.
MEASUREMENTS: Self-reported ART from first (January 1997–July 1997) to second (August 1997–January 1998) follow-up interviews. Drug abuse/dependence, severity of abuse, alcohol use, and probable mental disorders assessed in the first follow-up interview. Adjusted odds ratios (AORs) and 95% confidence intervals (CIs) estimated from weighted models for 1) receipt of any ART, and 2) receipt of HAART among those on ART.
RESULTS: Of our study population, ART was reported by 90% and HAART by 61%. Over one third had a probable mental disorder and nearly half had abused any drugs, but drug dependence (9%) or severe abuse (10%) was infrequent. Any ART was less likely for persons with dysthymia (AOR, 0.74; CI, 0.58 to 0.95) but only before adjustment for drug abuse. After full adjustment with mental health and drug abuse variables, any ART was less likely for drug dependence (AOR, 0.58; CI, 0.34 to 0.97), severe drug abuse (AOR, 0.52; CI, 0.32 to 0.87), and HIV risk from injection drug use (AOR, 0.55; CI, 0.39 to 0.79). Among drug users on ART, only mental health treatment was associated with HAART (AOR, 1.57; CI, 1.11 to 2.08).
CONCLUSIONS: Drug abuse-related factors were greater barriers to ART use in this national sample than mental disorders but once on ART, these factors were unrelated to type of therapy.
- Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279:450–4. CrossRef
- Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–60. CrossRef
- Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States. JAMA. 1999;281:2305–15. CrossRef
- Turner BJ, Markson LE, Mauskopf J, Houchens R, Fanning TR. Health care delivery, zidovudine use, and survival of women and men with AIDS. J Acquir Immune Defic Syndr. 1994;7:1250–62.
- Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA. 1998;280:544–6. CrossRef
- Michaels SH, Clark R, Kissinger P. Use of antiretroviral therapy by intravenous drug users with HIV (letter). JAMA. 1999;281:699–700. CrossRef
- Fairfield KM, Libman H, Davis RB, Eisenberg DM, Phillips RS. Delays in protease inhibitor use in clinical practice. J Gen Intern Med. 1999;14:395–401. CrossRef
- Williams JB, Rabkin JG, Remien RH, Gorman JM, Ehrhardt AA. Multidisciplinary baseline assessment of homosexual men with and without human immunodeficiency virus infection. II. Standardized clinical assessment of current and lifetime psychopathology. Arch Gen Psychiatry. 1991;48:124–30.
- Merikangas KR, Mehta RL, Molnar BE, et al. Comorbidity of substance use disorders with mood and anxiety disorders: results of the International Consortium in Psychiatric Epidemiology. Addict Behav. 1998;23:893–907. CrossRef
- Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an International Panel. JAMA. 1996;276:146–54. CrossRef
- Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA. 1997;277:1962–9. CrossRef
- Shapiro MF, Berk ML, Berry SH, et al. National probability samples in studies of low-prevalence diseases. Part I: Perspectives and lessons from the HIV Cost and Services Utilization Study. Health Serv Res. 1999;34:951–68.
- Frankel MR, Shapiro MF, Duan N, et al. National probability samples in studies of low-prevalence diseases. Part II: Designing and implementing the HIV Cost and Services Utilization Study sample. Health Serv Res. 1999;34:969–92.
- Phin J. Nonpatient polydrug users. In: Wesson DR, Carlin AS, Adams KM, et al, eds. Polydrug Abuse. The Results of a National Collaborative Study. New York, NY: Academic Press; 1978.
- Rost K, Burnam MA, Smith GR. Development of screeners for depressive disorders and substance disorder history. Med Care. 1993;31:189–99. CrossRef
- Caetano R. Prevalence, incidence and stability of drinking problems among Whites, Blacks, and Hispanics: 1984–1992. J Stud Alcohol. 1997;58:565–72.
- Kessler RC, Andrews G, Mroczek D, Ustun B, Wittchen H-U. The World Health Organization Composite International Diagnostic Interview Short Form (CIDI-SF). Int J Methods Psych Res. 1998;7:171–85. CrossRef
- Agresti A. Categorical Data Analysis. New York, NY: Wiley; 1990.
- Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998;280:547–9. CrossRef
- Ethridge RM, Craddock SG, Dunteman GH, Hubbard RL. Treatment services in two national studies of community-based drug abuse treatment programs. J Subst Abuse. 1995;7:9–26. CrossRef
- Turner BJ, Newschaffer CJ, Zhang D, Fanning TR, Hauck WW. Translating clinical trial results into practice: the effect of an AIDS clinical trial on prescribed antiretroviral therapy for HIV-infected pregnant women. Ann Intern Med. 1999;130:136–43.
- Bassetti S, Battegay M, Furrer H, et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 1999;21:114–9.
- Bogart LM, Kelly JA, Catz SL, Sosman JM. Impact of medical and nonmedical factors on physician decision making for HIV/AIDS antiretroviral treatment. J Acquir Immun Defic Syndr. 2000;23:396–404.
- Turner BJ, Newschaffer CJ, Zhang D, Cosler L, Hauck WW. Antiretroviral use and pharmacy-based measurement of adherence in post-partum HIV-infected women. Med Care. 2000;38:911–25. CrossRef
- Jones AM, Thaker H, Foley B, et al. A qualitative study on retroviral therapy: drug compliance in IVDU patients. Int Conf AIDS. 1998;12:593. Abstract no. 32361.
- McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, et al. The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9:199–213. CrossRef
- Stone VE, Adelson-Mitty J, Duefield CA, Steger KA, Stein MD, Mayer KH. Adherence to protease inhibitor (PI) therapy in clinical practice: usefulness of demographics, attitudes, and knowledge as predictors. Int Conf AIDS. 1998;12:588. Abstract no. 32337.
- Fiellin DA, Reid MC, O’Connor PG. Outpatient management of patients with alcohol problems. Ann Intern Med. 2000;133:815–27.
- Singh N, Squier C, Sivek C, Wagener M, Nguyen MH, Yu VL. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care. 1996;8:261–9. CrossRef
- Gordillo V, del Amo J, Soriano V, Gonzalez-Lahoz J. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS. 1999;10:1763–9. CrossRef
- Holzemer WL, Corless IB, Nokes KM, et al. Predictors of self-reported adherence in persons living with HIV disease. AIDS Patient Care STDS. 1999;13:185–97. CrossRef
- Andrews G, Peters L. The psychometric properties of the Composite International Diagnostic Interview. Soc Psychiatry Psychiatr Epidemiol. 1998;33:80–8. CrossRef
- Turvey CL, Wallace RB, Herzog R. A revised CES-D measure of depressive symptoms and a DSM-based measure of major depressive episodes in the elderly. Int Psychogeriatr. 1999;11:139–48. CrossRef
- Brooner RK, King VL, Kidorf M, Schmidt CW Jr, Bigelow GE. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry. 1997;54:71–80.
- Rabkin JG, Johnson J, Lin SH, et al. Psychopathology in male and female HIV-positive and negative injecting drug users: longitudinal course over 3 years. AIDS. 1997;11:507–15. CrossRef
- Cunningham WE, Markson LE, Andersen RM, et al. Prevalence and predictors of highly active antiretroviral therapy use in persons with HIV infection in the U.S. J Acquir Immune Defic Syndr. 2000;25:115–23. CrossRef
- Effects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected persons
Journal of General Internal Medicine
Volume 16, Issue 9 , pp 625-633
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- anti-HIV agents
- substance-related disorders
- substance abuse
- intravenous drug abuse
- mental disorders
- HIV infections
- Industry Sectors
- Author Affiliations
- 1. the Division of General Internal Medicine, Department of Medicine, University of Pennsylvania, Philadelphia, Pa
- 2. the Agency for Healthcare Research and Quality, Rockville, Md
- 3. the University of California at Los Angeles, Los Angeles, Calif
- 4. the Department of Sociology, Kent State University, Kent, Ohio
- 5. the RAND Health Program, Santa Monica, Calif
- 6. Center for AIDS Research, Education, and Services and Collaborative Alcohol Research Center, Charles R. Drew University of Medicine and Science, Los Angeles, Calif
- 7. the Division of General Internal Medicine, Rhode Island Hospital, Providence, RI
- 8. the University of California-San Diego, and the Veterans Affairs San Diego Health System, San Diego, Calif